trastuzumab derxutecan

Phase 2

trastuzumab derxutecan is one of 13 therapeutic programs targeting Breast Cancer Metastatic. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[2][1]

Indication

Breast Cancer MetastaticEnrolling by invitation

Breast Cancer MetastaticPhase 2

Enrolling by invitation

Competition

Competitive Landscape

12 competitors in Breast Cancer Metastatic

#DrugCompanyPhaseTrials

Taxol

Teva

Phase 2

1 2

Halaven

Eisai

Phase 2

1 3

Gemzar

Johnson & Johnson

Phase 2

1 4

Herceptin

OOrganon and Co

Phase 2

3 5

Xeloda

EEngelhard Arzneimittel GmbH & Co.KG

Phase 2

1 6

Navelbine

PPierre Fabre Medicament

Phase 2

1 7

Trastuzumab Deruxtecan

AstraZeneca

Phase 2

1 8

Evorpacept

AALX Oncology Inc.

Phase 2

1 9

Orserdu

SStemline Therapeutics, Inc.

Phase 1

1 10

Lynparza

AstraZeneca

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Breast Cancer Metastatic1 trial

A ctDNA Screening Program in Patients With HR+, HER2 Low Metastatic Breast Cancer for Detection of High-risk Relapse Patients on Any CDK4/6 Inhibitor Followed by a Single Arm Phase II Trial of Trastuzumab-deruxtecan in Patients With Persistent ctDNA After 1 Month of Treatment With Endocrine Therapy Combined With CDK4/6 Inhibitor

Enrolling by invitation·UUNICANCER·Phase 2·NCT06680596·80 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for trastuzumab derxutecan. U.S. National Library of Medicine, National Institutes of Health.
[2]
Open Targets Platform — Drug–disease associations for trastuzumab derxutecan. EMBL-EBI & Wellcome Sanger Institute.
[3]
SEC EDGAR — UNICANCER company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Highest Phase: Phase 2[1]
Company: UUNICANCER

trastuzumab derxutecan

Status by Indication[2][1]

Competitive Landscape

Trials by Indication[1]

Breast Cancer Metastatic1 trial

References

Drug Info

Quick Facts

Related News